Arcosa (ACA) Proxy filing summary

Executive summary

• Pending all-cash acquisition by CRH at $150 per share, expected to close in Q1 2027, subject to stockholder and regulatory approval.

• Special meeting scheduled for September 4, 2026, for stockholders to consider approval of the merger.

• Financial guidance suspended and no quarterly conference call due to the pending merger.

• Forward-looking statements highlight risks related to merger completion, regulatory approvals, and potential business disruptions.

Voting matters and shareholder proposals

• Stockholders are asked to approve the merger agreement with CRH at the special meeting.

Board of directors and corporate governance

• Directors and executive officers may be deemed participants in the proxy solicitation for the merger.

• Additional information on directors and officers, including their interests, is available in the proxy statement and other SEC filings.